Emily Hickey - Charles River President
| CRL Stock | USD 232.56 5.78 2.55% |
President
Dr. Emily Hickey was promoted as Corporationrationrate Senior Vice President Global Discovery Services of Company. Dr. Hickey is an experienced drug discovery executive with a proven track record for establishing and leading successful global discovery businesses. Before joining Charles River Dr. Hickey was the Executive Director of In Vivo Pharmacology at Merck Research Labs leading the development and implementation of the externalization strategy for in vivo studies. Most recently Dr. Hickey has served as Corporationrationrate Vice President In Vivo Discovery overseeing our in vivo discovery businesses in the United States and Europe. Dr. Katherine Hilyard Managing Director BioFocus DPI Ltd. will be promoted to the position of Corporationrationrate Vice President Early Discovery and will assume responsibility for the Argenta BioFocus and ChanTest businesses which comprise our Early Discovery business. since 2016.
| Tenure | 8 years |
| Address | 251 Ballardvale Street, Wilmington, MA, United States, 01887 |
| Phone | 781 222 6000 |
| Web | https://www.criver.com |
Charles River Management Efficiency
The company has Return on Asset of 0.0519 % which means that on every $100 spent on assets, it made $0.0519 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1438 %, implying that it generated $0.1438 on every 100 dollars invested. Charles River's management efficiency ratios could be used to measure how well Charles River manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Charles River's Return On Capital Employed is quite stable compared to the past year. Return On Assets is expected to rise to 0.06 this year, although the value of Return On Tangible Assets will most likely fall to 0.12. At this time, Charles River's Return On Assets are quite stable compared to the past year. Asset Turnover is expected to rise to 0.67 this year, although the value of Intangible Assets will most likely fall to about 480.2 M.Similar Executives
| Found 2 records | PRESIDENT Age | ||
| Vassiliki Economides | Kezar Life Sciences | 38 | |
| Hyam MD | Century Therapeutics | 66 | |
Management Performance
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0519 |
Charles River Labora Leadership Team
Elected by the shareholders, the Charles River's board of directors comprises two types of representatives: Charles River inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Charles. The board's role is to monitor Charles River's management team and ensure that shareholders' interests are well served. Charles River's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Charles River's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Craig Thompson, Director | ||
| Robert Bertolini, Independent Director | ||
| Birgit Girshick, Corporate Executive Vice President, Global Discovery and Safety Assessment, Biologics and Avian | ||
| James Foster, Chairman of the Board, President, Chief Executive Officer | ||
| Joseph LaPlume, Corporate Executive Vice President - Corporate Development and Strategy | ||
| Mark Mintz, Corporate Officer | ||
| Michael Knell, Corporate Senior Vice President Chief Accounting Officer | ||
| George Milne, Lead Independent Director | ||
| Thomas Ackerman, CFO and Corporate Executive VP | ||
| George Llado, Independent Director | ||
| Nancy Andrews, Independent Director | ||
| Victoria Creamer, Corporate Senior Vice President Chief People Officer. | ||
| JeanPaul Mangeolle, Independent Director | ||
| Gina Mullane, Chief VP | ||
| Richard Wallman, Independent Director | ||
| Pr Frearson, Corporate Officer | ||
| David Smith, Chief Financial Officer, Corporate Executive Vice President | ||
| James JD, CEO Chairman | ||
| Matthew Daniel, General VP | ||
| Nancy Gillett, Chief Scientific Officer, Corporate Executive Vice President | ||
| Martin Mackay, Independent Director | ||
| Virginia Wilson, Independent Director | ||
| Flavia Pease, Corporate Executive Vice President | ||
| Emily Hickey, Corporate Senior Vice President - Global Discovery Services | ||
| Amy Cianciaruso, Corporate Officer | ||
| Todd Spencer, Corporate Relations | ||
| David Johst, Corporate Executive Vice President - Human Resources, Chief Administrative Officer, General Counsel | ||
| Deborah Kochevar, Independent Director | ||
| William Barbo, Corporate Executive Vice President and Chief Commercial Officer | ||
| Stephen Chubb, Independent Director | ||
| Richard Reese, Independent Director | ||
| Davide Molho, Corporate Executive Vice President ; President Global Research Models & Services and Preclinical Services Operations | ||
| George Massaro, Independent Director | ||
| Susan Hardy, Corporate Vice President Investor Relations |
Charles Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Charles River a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0519 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 14.56 B | ||||
| Shares Outstanding | 51.51 M | ||||
| Shares Owned By Insiders | 0.97 % | ||||
| Shares Owned By Institutions | 99.03 % | ||||
| Number Of Shares Shorted | 1.58 M | ||||
| Price To Earning | 33.74 X |
Pair Trading with Charles River
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Charles River position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Charles River will appreciate offsetting losses from the drop in the long position's value.Moving together with Charles Stock
| 0.87 | A | Agilent Technologies Earnings Call This Week | PairCorr |
| 0.8 | BMY | Bristol Myers Squibb Earnings Call This Week | PairCorr |
Moving against Charles Stock
| 0.48 | GILD | Gilead Sciences Earnings Call This Week | PairCorr |
| 0.45 | EVO | Evotec SE ADR Earnings Call Tomorrow | PairCorr |
The ability to find closely correlated positions to Charles River could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Charles River when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Charles River - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Charles River Laboratories to buy it.
The correlation of Charles River is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Charles River moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Charles River Labora moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Charles River can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Charles River Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Charles Stock analysis
When running Charles River's price analysis, check to measure Charles River's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Charles River is operating at the current time. Most of Charles River's value examination focuses on studying past and present price action to predict the probability of Charles River's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Charles River's price. Additionally, you may evaluate how the addition of Charles River to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is Charles River's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Charles River. If investors know Charles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Charles River listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.01) | Earnings Share 9.23 | Revenue Per Share 80.61 | Quarterly Revenue Growth (0.08) | Return On Assets 0.0519 |
The market value of Charles River Labora is measured differently than its book value, which is the value of Charles that is recorded on the company's balance sheet. Investors also form their own opinion of Charles River's value that differs from its market value or its book value, called intrinsic value, which is Charles River's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Charles River's market value can be influenced by many factors that don't directly affect Charles River's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Charles River's value and its price as these two are different measures arrived at by different means. Investors typically determine if Charles River is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Charles River's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.